-transparent.png){kind=logo}
Because "the standard" chemotherapy for advanced gastric adenocarcinoma, the FAM combination of 5-fluorouracil, adriamycin, and mitomycin, is only minimally effective, there is a clear need for other choices. Therefore, the Southwest Oncology Group tested the new adriamycin analog, bisantrene, hoping that it might be more effective than the "parent drug." Twenty-six patients with gastric adenocarcinoma were treated on a program of every-3-week 2-hour bisantrene infusions. The starting dose was 260 mg/m2 (208 if poor risk), with subsequent doses based on prior toxicity. The regimen caused sufficient toxicity (especially local phlebitis with pain and swelling) to assure an adequate test. One person (3.8% of eligible patients) experienced a clinically useful 3-month response. He had previously had progressive disease on FAM. Nevertheless, we conclude that bisantrene is not an addition to the small list of drugs useful in the management of gastric adenocarcinoma.
F J Panettiere, and
S E Jones, and
N Oishi, and
H J Eyre, and
R M O'Bryan, and
W A Andes, and
S A Taylor, and
P N Grozea
January 1987,
Investigational new drugs,
F J Panettiere, and
S E Jones, and
N Oishi, and
H J Eyre, and
R M O'Bryan, and
W A Andes, and
S A Taylor, and
P N Grozea
January 1986,
Cancer chemotherapy and pharmacology,
F J Panettiere, and
S E Jones, and
N Oishi, and
H J Eyre, and
R M O'Bryan, and
W A Andes, and
S A Taylor, and
P N Grozea
November 1987,
Cancer treatment reports,
F J Panettiere, and
S E Jones, and
N Oishi, and
H J Eyre, and
R M O'Bryan, and
W A Andes, and
S A Taylor, and
P N Grozea
December 1989,
American journal of clinical oncology,
F J Panettiere, and
S E Jones, and
N Oishi, and
H J Eyre, and
R M O'Bryan, and
W A Andes, and
S A Taylor, and
P N Grozea
November 1991,
Investigational new drugs,
F J Panettiere, and
S E Jones, and
N Oishi, and
H J Eyre, and
R M O'Bryan, and
W A Andes, and
S A Taylor, and
P N Grozea
May 1984,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
F J Panettiere, and
S E Jones, and
N Oishi, and
H J Eyre, and
R M O'Bryan, and
W A Andes, and
S A Taylor, and
P N Grozea
May 1986,
Cancer treatment reports,
F J Panettiere, and
S E Jones, and
N Oishi, and
H J Eyre, and
R M O'Bryan, and
W A Andes, and
S A Taylor, and
P N Grozea
January 1983,
Investigational new drugs,
F J Panettiere, and
S E Jones, and
N Oishi, and
H J Eyre, and
R M O'Bryan, and
W A Andes, and
S A Taylor, and
P N Grozea
August 1991,
Journal of the National Cancer Institute,
F J Panettiere, and
S E Jones, and
N Oishi, and
H J Eyre, and
R M O'Bryan, and
W A Andes, and
S A Taylor, and
P N Grozea
January 1985,
Cancer treatment reports,
